In CD19 CAR T-cell therapy, ICANS ranges from altered consciousness to severe brain edema, while in BCMA CAR T-cell therapy, notable toxicity, such as parkinsonism, has occurred in pivotal clinical trials for multiple myeloma [24,25], consistent with the findings of this study. The gene discussed is CD19; the disease is Parkinson disease.